Johnson & Johnson in Talks to Buy Protagonist Therapeutics
PositiveFinancial Markets

Johnson & Johnson is in discussions to acquire Protagonist Therapeutics, a move that could significantly enhance their collaboration on a treatment for ulcerative colitis. This acquisition is important as it not only strengthens their existing partnership but also highlights the growing focus on innovative therapies in the healthcare sector.
— Curated by the World Pulse Now AI Editorial System